Elanco Appoints New Chief Legal Officer

TL;DR

Elanco names Kate Nealon as new CLO, effective April 1st. Big salary, big stock options incoming.

AI Summary

Elanco Animal Health Inc. announced on March 29, 2024, the appointment of Ms. Katharine P. (Kate) Nealon as Executive Vice President, Chief Legal Officer and Corporate Secretary, effective April 1, 2024. Ms. Nealon will receive an annual base salary of $450,000 and will be eligible for the company's annual incentive plan and long-term equity awards. This appointment follows the departure of Mr. Philip A. (Phil) Laskawy, Jr. from his role as Executive Vice President, Chief Legal Officer and Corporate Secretary.

Why It Matters

The appointment of a new Chief Legal Officer can signal a shift in legal strategy or a focus on specific compliance areas, impacting the company's risk management and corporate governance.

Risk Assessment

Risk Level: low — This filing primarily concerns an executive appointment and associated compensation, which is a routine corporate event.

Key Numbers

• $450,000 — Annual Base Salary (For the new Chief Legal Officer, Kate Nealon.)

Key Players & Entities

• Elanco Animal Health Inc. (company) — Registrant
• Katharine P. (Kate) Nealon (person) — Newly appointed Executive Vice President, Chief Legal Officer and Corporate Secretary
• $450,000 (dollar_amount) — Annual base salary for Ms. Nealon
• April 1, 2024 (date) — Effective date of Ms. Nealon's appointment
• Philip A. (Phil) Laskawy, Jr. (person) — Departing Executive Vice President, Chief Legal Officer and Corporate Secretary

FAQ

From the Filing

0001104659-24-041558.txt : 20240401 0001104659-24-041558.hdr.sgml : 20240401 20240401082515 ACCESSION NUMBER: 0001104659-24-041558 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240329 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 24805699 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm245182d2_8k.htm FORM 8-K false 0001739104 0001739104 2024-03-29 2024-03-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934     Date of Report (Date of Earliest Event Reported): March 29, 2024   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 1.01 Entry into a Material Definitive Agreement.   On March 29, 2024, Elanco Animal Health Incorporated (the “Company”) entered into a cooperation agreement (the “Cooperation Agreement”) with Ancora Catalyst Institutional, LP and certain of its affiliates (together, the “Ancora Parties”).   Pursuant to the Cooperation Agreement, the Company has appointed Kathy V. Turner and Craig S. Wallace to the Company’s Board of Directors (the